StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) company profile

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)

Close on Nov 17, 2026Market cap $253.10MP/E –Yield –

About Enanta Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing small molecule oral drug candidates for virology and immunology indications. Within virology, the company discovered glecaprevir, an antiviral protease inhibitor co-formulated in AbbVie's combination treatments for hepatitis C virus, and develops clinical-stage candidates targeting respiratory syncytial virus, COVID-19, and hepatitis B virus. In immunology, Enanta targets biological mechanisms such as KIT and STAT6 to design therapies for type 2 inflammatory diseases, focusing proof-of-concept efforts on conditions such as chronic spontaneous urticaria and atopic dermatitis. The company engages in collaborative partnerships and utilizes contract research organizations for development and commercialization.

The company maintains its principal executive offices in Watertown, Massachusetts. Enanta conducts preclinical studies and clinical trials targeting domestic and global patient populations affected by serious viral infections and chronic inflammatory conditions. Development operations are performed through contract research facilities and collaborative relationships.

Summary of the business section of Enanta Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Enanta Pharmaceuticals Inc
Founded
1995
Headquarters
Watertown, MA
Address
4 Kingsbury Avenue 02472
Phone
(617) 607-0800
Employees
120, Sep 30, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
September 30
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ENTA
Exchange
Nasdaq
IPO date
Mar 21, 2013
Shares outstanding
29M, Aug 7, 2026
Public float
$110.59M, Mar 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1177648
CUSIP
29251M106
ISIN
US29251M1062
FIGI
BBG001V9NSB4
Share class FIGI
BBG001V9NSC3
LEI
529900SSN4DODDQSN594
EIN
04-3205099

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jay R. LulyPresident and CEO, Director871,871
Scott T. RottinghausChief Medical Officer23,787
Yat Sun OrChief Scientific Officer374,854
Brendan LuuChief Business Officer44,891
Tara Lynn KiefferChief Product Strategy Officer32,195
Matthew Paul KowalskyChief Legal Officer3,591
Harry R. Trout IIISee Remarks16,348
Kathleen S. CappsSee Remarks8,377
Paul J. MellettChief Fin. & Admin Officer99,210
Lesley RussellDirector–
Yujiro S. HataDirector–
Kristine PetersonDirector–
Mark G. FolettaDirector–
Bruce L. A. CarterDirector0
Terry VanceDirector5,800

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.77M$3.60M$1.32M$23–
FY2024$2.70M$2.19M$1.27M$20–
FY2023$7.86M-$2.47M$2.81M$22–
FY2022$5.29M$6.33M$2.11M$124$119

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jay R. Luly
President and Chief Executive Officer
$803.30K$128.55K$1.22M$591.67K$22.06K$2.77M+3%
Scott T. Rottinghaus
Chief Medical Officer
$560.30K$53.56K$425.94K$281.35K$22.06K$1.34M+7%
Yat Sun Or
Chief Scientific Officer
$553.15K$53.56K$425.94K$239.37K$21.76K$1.29M+6%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 21, 2013
Offer price
$14.00
Securities offered
4,000,000
Gross proceeds
$56.00M
Exchange
Nasdaq
First trading day
Mar 21, 2013
First-day close
$17.18+22.7%
Lock-up ends (est.)
Sep 17, 2013

“The initial public offering price of our common stock is $14.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of September 30, 2025, we had 120 full-time employees, 61 of whom hold Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?